Cardiovascular Inflammation Reduction TrialStatus: open
[433957-19] Cardiovascular Inflammation Reduction Trial (CIRT): A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients.
Treatment for Coronary Artery Disease
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH). IRB Number 13-082
SponsorsThis trial is sponsored by National Heart Lung and Blood Institute.
Interested in Clinical Trial?
Providers Associated With This Trial
- Ghulam Mustafa Awan, M.D.Interventional CardiologistDirector of Interventional Cardiology and Endovascular Interventions; Associate Professor of Internal Medicine